Document Detail

Occipital condyle syndrome guiding diagnosis to metastatic prostate cancer.
MedLine Citation:
PMID:  16882081     Owner:  NLM     Status:  MEDLINE    
Occipital condyle syndrome (OCS) results from a unilateral occipital pain associated with an ipsilateral paresis of the 12th cranial nerve (hypoglossal), and is typically caused by metastasis of the skull base. OCS diagnosis occurred, in all cases described in the published literature, when metastatic prostate cancer (MPC) was previously known. We present a case of a patient whose initial manifestation of MPC was OCS. The patient was treated with complete hormonal blockade and non-steroidal anti-inflammatory drugs as opposed to locoregional radiotherapy applied in other cases. After 18 month follow-up, the patient had a complete neurological and biochemical response.
Juan Ignacio Martinez Salamanca; Concepcion Murrieta; Jose Jara; Jose Luis Munoz-Blanco; Federico Alvarez; Juan Guzman De Villoria; Carlos Hernandez
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International journal of urology : official journal of the Japanese Urological Association     Volume:  13     ISSN:  0919-8172     ISO Abbreviation:  Int. J. Urol.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-08-02     Completed Date:  2006-11-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440237     Medline TA:  Int J Urol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  1022-4     Citation Subset:  IM    
Department of Urology, Hospiatal Gregorio Maranon, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / diagnosis,  secondary*
Diagnosis, Differential
Magnetic Resonance Imaging
Occipital Bone*
Prostatic Neoplasms / pathology*,  radiography,  ultrasonography
Skull Base Neoplasms / diagnosis,  secondary*
Tomography, X-Ray Computed

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone ref...
Next Document:  Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example...